GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on Jun 27, 2025. Further, the company has submitted the Exchange a copy of Srutinizers report along with copy of minutes.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals held its 100th Annual General Meeting on June 27, 2025, via video conferencing. All six resolutions put to vote were approved with the requisite majority. Shareholders adopted the audited financial statements (including consolidated) for FY ending March 31, 2025, and confirmed a final dividend of Rs 42 per equity share. Mr. Juby Chandy was re-appointed as a director (retiring by rotation), and Dr. (Ms.) Sunita Maheshwari was re-appointed as an Independent Director via a special resolution. Parikh & Associates were appointed as Secretarial Auditors, and the remuneration of the Cost Auditor was ratified. Voting was overwhelmingly in favour across all resolutions, ranging from 98.30% to 100%.
Routine governance outcome with strong shareholder approval on all items. The confirmed Rs 42 final dividend benefits shareholders, and smooth passage of board appointments signals no governance concerns. Minimal impact on stock price expected as outcomes were in line with expectations.